R 911Alternative Names: R-911
Latest Information Update: 21 Jul 2016
At a glance
- Originator Radikal Therapeutics
- Class Peptides
- Mechanism of Action Reactive oxygen species modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute lung injury; Bronchopulmonary dysplasia; Kidney disorders